| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net sales | 5,065 | 5,061 | 4,663 | 4,209 |
| Cost of products sold (excluding amortization expense) | 1,523 | 1,637 | 1,453 | 1,312 |
| Gross profit | 3,542 | 3,424 | 3,210 | 2,897 |
| Selling, general and administrative expenses | 1,741 | 1,716 | 1,597 | 1,562 |
| Research and development expenses | 514 | 526 | 443 | 407 |
| Royalty expense | 12 | 14 | 14 | 5 |
| Amortization expense | 225 | 225 | 219 | 205 |
| Intangible asset impairment charges | 0 | 46 | - | 0 |
| Contingent consideration net expense (benefit) | 11 | -5 | 5 | -23 |
| Restructuring net charges (credits) | -8 | 83 | 10 | 8 |
| Litigation-related net charges (credits) | - | - | - | 0 |
| Operating expenses | 2,494 | 2,605 | 2,288 | 2,164 |
| Operating income (loss) | 1,048 | 819 | 921 | 733 |
| Interest expense | 87 | 90 | 82 | 79 |
| Other, net | -23 | 213 | -34 | 14 |
| Income (loss)before income taxes | 939 | 941 | 805 | 669 |
| Income tax expense (benefit) | 183 | 146 | 133 | 200 |
| Net income (loss) | 755 | 795 | 672 | 468 |
| Preferred stock dividends | - | - | - | 0 |
| Net income (loss) attributable to noncontrolling interests | 0 | -2 | -2 | 0 |
| Net income (loss) attributable to boston scientific common stockholders | 755 | 797 | 674 | 469 |
| Basic | 1,481,700,000 | 1,479,900,000 | 1,477,200,000 | 1,472,700,000 |
| Diluted | 1,495,500,000 | 1,493,500,000 | 1,493,100,000 | 1,487,400,000 |
| Net income (loss)per common share basic | 0.51 | 0.54 | 0.46 | 0.32 |
| Net income (loss)per common share diluted | 0.51 | 0.53 | 0.45 | 0.32 |
BOSTON SCIENTIFIC CORP (BSX)
BOSTON SCIENTIFIC CORP (BSX)